Translate the keyword into a target product profile
The first technical task is to translate the keyword into measurable product requirements. For EFSA compliant peptide ODF film, the brief should identify peptide sequence or commercial name, molecular form, counterion, source, purity, assay basis, proposed amount per strip, daily use, target market and intended statements. Those inputs determine whether laboratory screening is meaningful and whether the project belongs on a food-supplement, research or medicinal pathway.
Technical feasibility factors
The same strip can be classified differently when the ingredient, amount, claims or market changes. A responsible plan reviews ingredient history, novel-food or new-dietary-ingredient questions, drug status, permitted claims, label format and importer responsibilities before commercial sampling.
Terms such as “FDA compliant,” “clinical grade” or “EFSA compliant” are not blanket product approvals. Compliance is demonstrated through the applicable pathway, records, evidence and truthful labeling for the specific product.
Quality evidence to request
Supplier documentation is useful only when it matches the lot, method and proposed use. Request the peptide specification, certificate of analysis, test methods, impurity information, origin and storage conditions. For the finished film, define sampling and acceptance criteria before scale-up.
- Raw-material identity and assay on an appropriate basis
- Uniformity strategy across the mixed mass, cast web and cut units
- Moisture, appearance, mechanical handling and disintegration controls
- Packaging seal verification and stability-indicating observations
- Deviation, change-control and traceability records
Regulatory and claims boundary
Claims must follow the product’s legal category. In the United States, dietary-supplement structure/function claims require substantiation and must not become disease claims. New dietary ingredient questions may also require premarket work. In the European Union, novel-food status and the authorized-claims framework require separate review.
Neither “sublingual” nor “needle free” automatically establishes a permitted claim. If the commercial proposition depends on systemic delivery, treatment, pharmacological action or equivalence to a drug, the project needs specialist drug-regulatory and clinical assessment.
Questions to put in the RFQ
- What is the proposed legal category in each destination market?
- Is the exact ingredient eligible at the proposed amount and route?
- Which claims require substantiation, notification or authorization?
- Which party owns importer, notification and post-market duties?
Export readiness is product- and country-specific
A factory certificate cannot substitute for ingredient eligibility, importer obligations, label language or notification requirements. Build a destination-market dossier for the exact formula and pack, and avoid blanket statements that imply a regulator has approved the entire product.
A practical development sequence
- Classify the ingredient, intended use and route in each market.
- Review eligibility, notifications, authorizations and claims.
- Align the technical dossier, label and importer responsibilities.
- Recheck the pathway whenever formula, dose, route or claims change.
Technical deep dive for this project brief
Artwork control
Primary-pack artwork is a controlled specification. Version approval should cover product identity, ingredients, directions, warnings, lot and expiry fields, manufacturer or distributor information, country-specific text and print readability after sealing.
Assay basis
Peptide content may be reported as supplied material, anhydrous material, free peptide or a salt. The calculation basis must be fixed before dose targets are compared, because water, counterions and non-peptide components can create a meaningful difference between weighed material and labeled peptide amount.
Purity and related substances
A single headline purity value may not describe individual impurities, aggregates, residual solvents or synthesis-related residues. The risk assessment should identify which impurity classes matter, how the method separates them and whether limits remain appropriate after film processing and storage.
Aggregation risk
Peptides can associate at interfaces or under changes in concentration, temperature, pH and shear. Visual clarity alone may miss aggregation. The analytical plan should consider whether aggregation could affect assay, impurities, film distribution or biological risk for the intended pathway.
Frequently asked questions
Is EFSA compliant peptide ODF film automatically suitable for oral film?
No. Loading, solubility or dispersion, stability, taste, analytical control and ingredient status must be screened using the exact commercial material.
Does fast disintegration prove fast or high absorption?
No. Disintegration is a dosage-form performance measure. Absorption and effectiveness require separate, route-specific evidence.
What should a brand send for an initial review?
Provide the peptide specification, target amount, intended market and claims, preferred flavor, pack count, forecast and launch timeline.
Related development resources
Review our Peptide Oral Strips development page, oral strip product matrix, OEM/ODM services and feasibility inquiry form.
Authoritative references
- FDA: Structure/Function Claims
- FDA: Dietary Supplement CGMPs
- FDA: New Dietary Ingredient Notification Process
- European Commission: Novel Food Status Catalogue
- European Commission: Nutrition and Health Claims
Request a Peptide Strip Feasibility Review